Archive | Of Interest

Scientists identify key driver in BRAF inhibitor resistant melanoma

Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Moffitt researchers identify metastasis driver in BRAF inhibitor resistant melanoma

TAMPA, Fla. — Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Targeted combination immunotherapy improved survival in stage III melanoma

Response: Based on molecular biology analysis, a substantial proportion of melanomas are driven by mutations of BRAF resulting in an ongoing growth activating signal. Based on the key role of BRAF several multiple kinase molecules have been developed in order to target this crucial pathway. These medications have shown to improve progression free survival and […]

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Adjuvant therapy in stage IIIA melanoma: Cost vs Benefit of gene profiling

Response: Indications for adjuvant therapy for resected, high-risk melanoma is a controversial and rapidly-evolving topic in melanoma treatment.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest